IL-6
Product Number 105236
Interleukin 6 (IL-6) is a multifunctional cytokine involved in both pro-inflammatory and anti-inflammatory processes. Rapidly upregulated in response to tissue damage or infection, IL-6 stimulates acute immune reactions and plays a pivotal role in adaptive immunity, driving the differentiation of B cells into antibody-producing cells and T cells into effector cells. Dysregulated IL-6 levels have been linked to autoimmune diseases, chronic inflammatory conditions, and certain cancers.
The Simoa® IL-6 Advantage PLUS Assay (Product #105236) offers unparalleled sensitivity and consistency for IL-6 measurement. This single-plex assay delivers sub-picogram sensitivity, powered by the fully automated HD-X™ platform. Designed for robust performance, it ensures lot-matched consistency for large-scale and longitudinal studies.
For multiplex analysis, the Simoa® Cytokine 4-Plex C (C4PC) Advantage PLUS Assay also enables precise measurement of IL-6 alongside IL-2, IL-8, and IFN-γ. Both assays are harmonized for comparable IL-6 results, providing flexibility for diverse research needs.
Data Sheet
Certificates Of Analysis
Applications and Intended Use
Simoa® IL-6 Advantage PLUS assay is intended for the quantitative detection of IL-6 in human serum and EDTA plasma samples.
For research use only.
Assay Specifications*
- Compatible instruments: HD-X
- Analytical Lower Limit of Quantification (LLOQ): 0.028 pg/mL
- Lower Limit of Detection (LOD): 0.01 pg/mL
- Dynamic range: 0 – 160 pg/mL
*IL-6 assay is also available in Simoa® Advantage kit version, compatible with HD-X and SR-X. For detailed specifications please refer to the datasheet.
Kit Contents
The assay kit includes all necessary reagents and controls to perform 96 tests.
Related Resources
- Moderate Blast Exposure Results In Increased IL-6 And TNFA In Peripheral Blood | Quanterix
- PLASMA IL-6 Changes Correlate To PD-1 Inhibitor Responses In NSCLC | Quanterix
- IL-6 production by monocytes is associated with graft function decline in patients with borderline changes suspicious for acute T-cell-mediated rejection: a pilot study | Quanterix